Galapagos has agreed with Janssen Pharmaceutica that Galapagos will regain full and unencumbered rights to the entire GPR84 program going forward, which includes the inhibitor GLPG1205 and its backup compound GLPG2196. No further details were disclosed.
|Searching for more deal information? Current Partnering offers the following options:|
GLPG1205 ('1205), works on GPR84, a novel mechanism of action developed by Galapagos for Inflammatory Bowel Diseases (IBD). Earlier this year, Galapagos presented compelling pre-clinical evidence for GPR84 playing a key role in IBD pathology.
The discovery of a selective antagonist of GPR84 led to GLPG1205, which shows strong efficacy in relevant pre-clinical models for IBD. Galapagos disclosed last year that '1205 showed good safety, target engagement, and favorable drug-like properties in Phase 1 studies in healthy volunteers.
Galapagos plans to initiate Phase 2 trial patient recruitment before year end 2014.
For further deal information visit Current Agreements (subscription required)
Scorecard: Top partnering deals by value in 2014
Report: Top 50 Big Biotech Partnering and M&A Deal Trends